Medical application of microencapsulating hybridoma cells in agarose microbeads `cytomedicine': therapeutic effect on IgG1 plasmacytosis and mesangio-proliferative glomerulonephritis in the interleukin 6 transgenic mouse

• Published in: Journal of controlled release Vol. 44; no. 2; pp. 195 - 200
• Main Authors: Okada, Naoki, Miyamoto, Hajime, Kaneda, Yoshihisa, Yamamoto, Yoko, Katsume, Asao, Saito, Hiroyuki, Yorozu, Keigo, Ueda, Otoya, Tsutsumi, Yasuo, Nakagawa, Shinsaku, Ohsugi, Yoshiyuki, Mayumi, Tadanori
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 17.02.1997; Elsevier
• Subjects: Agarose microencapsulation; Biological and medical sciences; Cytomedicine; Drug delivery system; General pharmacology; Human interleukin 6 transgenic mouse; Medical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; SK2 hybridoma cells; SK2 hybridoma cells; Cytomedicine; Human interleukin 6 transgenic mouse; Drug delivery system; Agarose microencapsulation; Kidney disease; Delivery system; Intraperitoneal administration; Urinary system disease; Pharmaceutical technology; Secretion; Rodentia; Cytokine; Transgenic animal; Hybridoma; Drug carrier; IgG1; Monoclonal antibody; Agarose; Interleukin 6; Vertebrata; Plasmacytosis; Mammalia; Mouse; Microencapsulation; Mesangial proliferative glomerulonephritis; Therapeutic role
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/S0168-3659(96)01522-2

We conducted preliminary studies to examine the feasibility of using microencapsulated living cells as carriers of bioactive drugs (`cytomedicine') to test our premise that such a novel drug delivery system would have certain advantages as a long-term delivery system for hormones, enzymes and other biomolecules in vivo. As graft rejection occurs when living cells are implanted in allogeneic or xenogeneic recipients, accordingly we used agarose microencapsulation technique to prevent destruction of the implanted cells by the host's immune system. Human interleukin 6 (hIL-6) transgenic mice, which develop massive IgG1 plasmacytosis and mesangio-proliferative glomerulonephritis with age, were intraperitoneally injected with agarose microbeads containing SK2 hybridoma cells (SK2 cells), which secrete anti-hIL-6 monoclonal antibodies. These mice demonstrated therapeutic response with reduced IgG1 plasmacytosis and proteinuria, and they also showed prolongation of survival time compared with the untreated group. These results are encouraging evidence that cytomedicine has potential application as an effective long-term delivery system of bioactive drugs in vivo.